Tumor burden assessed by the maximum standardized uptake value and greatest diameter on FDG-PET predicts prognosis in untreated diffuse large B-cell lymphoma

Nuclear Medicine and Molecular Imaging

Volumn 44, Issue 1, 2010, Pages 39-44

  Nguyen, Xuan Canh ^a,c   Lee, Won Woo ^a,b   Amin, Amr Mohamed ^a,d   Eo, Jae Seon ^a   Bang, Soo Mee ^a   Lee, Jong Seok ^a   Kim, Sang Eun ^a,b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c CHO RAY HOSPITAL   (Viet Nam)

^d CAIRO UNIVERSITY   (Egypt)

Author keywords

FDG PET; Greatest diameter; Lymphoma; Prognosis; Size incorporated maxSUV; SUV

Indexed keywords

FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER STAGING; CLINICAL ARTICLE; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; MALE; OVERALL SURVIVAL; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; QUESTIONNAIRE; SEX DIFFERENCE; TUMOR VOLUME;

EID: 79952770356     PISSN: 18693474     EISSN: 18693482     Source Type: Journal    
DOI: 10.1007/s13139-009-0009-0     Document Type: Article

References (25)

1. Jhanwar YS, Straus DJ. (2006) The role of PET in lymphoma. J Nucl Med 47:1326-1334
2. Lossos IS, Morgensztern D. (2006) Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 24:995-1007
3. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. (1993) A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994
4. 18F-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma-comparison with CT. Leuk Lymphoma 39:543-553
5. 18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 19:414-419
6. 18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 115:272-278
7. 18F-fluoro-deoxyglucose positron emission tomography in chemosensitive relapsed lymphoma. Br J Haematol 123:282-287
8. Okada J, Yoshikawa K, Itami M, Imaseki K, Uno K, Itami J, et al. (1992) Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 33:325-329
9. Lapela M, Leskinen S, Minn HR, Lindholm P, Klemi PJ, Soderstrom KO, et al. (1995) Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 86:3522-3527
10. Rodriguez M, Rehn S, Ahlstrom H, Sundstrom C, Glimelius B. (1995) Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med 36:1790-1796
11. 18Fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 23:4643-4651
12. Israel O, Keidar Z, Bar-Shalom R. (2004) Positron emission tomography in the evaluation of lymphoma. Semin Nucl Med 34:166-179
13. Leskinen-Kallio S, Ruotsalainen U, Nagren K, Teras M, Joensuu H. (1991) Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: a PET study. J Nucl Med 32:1211-1218
14. Mackintosh JF, Cowan RA, Jones M, Harris M, Deakin DP, Crowther D. (1988) Prognostic factors in stage I and II high and intermediate grade non-Hodgkin's lymphoma. Eur J Cancer Clin Oncol 24:1617-1622
15. Oguchi M, Ikeda H, Isobe K, Hirota S, Hasegawa M, Nakamura K, et al. (2000) Tumor bulk as a prognostic factor for the management of localized aggressive non-Hodgkin's lymphoma: a survey of the Japan lymphoma radiation therapy group. Int J Radiat Oncol Biol Phys 48:161-168
16. Wilder RB, Rodriguez MA, Ha CS, Pro B, Hess MA, Cabanillas F, et al. (2001) Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma. Cancer 91:2440-2446
17. Coiffier B. (1999) How to interpret the radiological abnormalities that persist after treatment in non-Hodgkin's lymphoma patients? Ann Oncol 10:1141-1143
18. 18F]fluoro-2-deoxy-D-glucose positron emission tomography. (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 106:1376-1381
19. Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. (2005) FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 16:1514-1523
20. Downey RJ, Akhurst T, Gonen M, Vincent A, Bains MS, Larson S, et al. (2004) Preoperative F-18 fluorodeoxyglucosepositron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 22:3255-3260
21. Leboulleux S, Dromain C, Bonniaud G, Auperin A, Caillou B, Lumbroso J, et al. (2006) Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab 91:920-925
22. 18F-FDG PET in Hurthle cell thyroid cancer patients. J Nucl Med 47:1260-1266
23. Nguyen XC, Lee WW, Chung JH, Park SY, Sung SW, Kim YK, et al. (2007) FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values. Eur J Radiol 62:214-219
24. Song YS, Lee WW, Chung J-H, Park SY, Kim YK, Kim SE. (2007) Tumor burden assessed bymaxSUVandmetabolic size on FDG-PET predicts prognosis of small cell lung cancer. J Nucl Med [abstract]
25. 18)F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. doi:10.1007/s00259-009-1275-x